Jefferies Maintains a 'Buy' on Celgene (CELG); Positive Feedback in Myeloma Survey

August 21, 2012 7:15 AM EDT Send to a Friend
Get Alerts CELG Hot Sheet
Price: $115.17 -1.72%

Rating Summary:
    22 Buy, 8 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 9 | Down: 8 | New: 32
Trade CELG Now!
Join SI Premium – FREE
Jefferies maintains a 'Buy' on Celgene (NASDAQ: CELG) price target of $81.00 (from $80.00).

Analyst, Thomas Wei, said, "We conducted a survey of 54 US multiple myeloma (MM) physicians. Feedback on Revlimid maintenance was incrementally positive for penetration and therapy duration, and we are raising our estimates and price target to $81 to account for longer duration of Revlimid therapy and higher pomalidomide penetration."

FY12 raised from $4.72 to $4.78 and FY13 from $4.73 to $4.79.

For an analyst ratings summary and ratings history on Celgene click here. For more ratings news on Celgene click here.

Shares of Celgene closed at $70.81 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change

Related Entities

Jefferies & Co

Add Your Comment